Supervised Exercise Training Counterbalances the Adverse Effects of Insulin Therapy in Overweight/Obese Subjects With Type 2 Diabetes
- Stefano Balducci, MD1,2,3⇓,
- Silvano Zanuso, PHD4,
- Patrizia Cardelli, PHD1,5,
- Gerardo Salerno, BS1,5,
- Sara Fallucca, PHD1,5,
- Antonio Nicolucci, MD, PHD6,
- Giuseppe Pugliese, MD, PHD1,2 and
- for the Italian Diabetes Exercise Study (IDES) Investigators*
- 1Department of Clinical and Molecular Medicine, “La Sapienza” University, Rome, Italy
- 2Diabetes Unit, Sant’Andrea Hospital, Rome Italy
- 3Metabolic Fitness Association, Monterotondo, Rome, Italy
- 4School of Science, University of Greenwich, London, U.K.
- 5Laboratory of Clinical Chemistry, Sant’Andrea Hospital, Rome, Italy
- 6Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, S. Maria Imbaro, Chieti, Italy
- Corresponding author: Stefano Balducci, sbalducci{at}esinet.it.
Abstract
OBJECTIVE To examine the effect of supervised exercise on traditional and nontraditional cardiovascular risk factors in sedentary, overweight/obese insulin-treated subjects with type 2 diabetes from the Italian Diabetes Exercise Study (IDES).
RESEARCH DESIGN AND METHODS The study randomized 73 insulin-treated patients to twice weekly supervised aerobic and resistance training plus structured exercise counseling (EXE) or to counseling alone (CON) for 12 months. Clinical and laboratory parameters were assessed at baseline and at the end of the study.
RESULTS The volume of physical activity was significantly higher in the EXE versus the CON group. Values for hemoglobin A1c, BMI, waist circumference, high-sensitivity C-reactive protein, blood pressure, LDL cholesterol, and the coronary heart disease risk score were significantly reduced only in the EXE group. No major adverse events were observed.
CONCLUSIONS In insulin-treated subjects with type 2 diabetes, supervised exercise is safe and effective in improving glycemic control and markers of adiposity and inflammation, thus counterbalancing the adverse effects of insulin on these parameters.
Footnotes
-
Clinical trial reg. no. ISRCTN04252749, www.isrctn.org.
-
This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1450/-/DC1.
-
↵* A complete list of the IDES Investigators can be found in the Supplementary Data.
- Received August 1, 2011.
- Accepted September 26, 2011.
- © 2012 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
